Filing Imminent As Mycovia’s Antifungal Prevents Recurrent Vulvovaginal Candidiasis

Private Company Is Preparing For Commercialization, Talking To Partners

 
• By Mandy Jackson
Oteseconazole prevented recurrent vulvovaginal candidiasis in more than 90% of women in the VIOLET studies • Source: Shutterstock

More from Strategy

More from Business